D
Zai Lab Limited ZLAB
$31.84 -$0.59-1.82% NASDAQ
Recommendation
Prev Close
$31.84
Volume
478
Avg Vol (90D)
1,011,863
Market Cap
$3.50B
Dividend & Yield
--
52-Week Range
$15.67 - $39.77
P/E (TTM)
--
EPS (TTM)
-$25.92
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Zai Lab (ZLAB, $32) price exceeded its 50-day Moving Average on April 25, 2025
4/26/2025 - Tickeron - Stocks
Zai Lab Ltd (ZLAB) Unveils Promising Oncology Therapies at AACR 2025 ZLAB stock news
4/25/2025 - GuruFocus
Zai Lab (ZLAB) to Showcase Promising Cancer Therapy Data at AACR 2025 ZLAB Stock News
4/25/2025 - GuruFocus
Zai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology ...
4/25/2025 - GuruFocus
Zai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology ...
4/25/2025 - GuruFocus
Zai Lab presents data from studies evaluating two oncology therapies
4/25/2025 - TipRanks Financial Blog
Zai Lab presents data from studies evaluating two oncology therapies
4/25/2025 - The Fly
Zai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology Therapies at AACR 2025
4/25/2025 - Business Wire
Marshall Wace LLP Acquires Shares of 288,992 Zai Lab Limited (NASDAQ:ZLAB)
4/25/2025 - MarketBeat
Zai Lab (NASDAQ:ZLAB) Shares Gap Up - Still a Buy?
4/24/2025 - MarketBeat
Zai Lab (ZLAB, $33.62) Moving Average Convergence Divergence (MACD) Histogram turned positive on April 23, 2025
4/24/2025 - Tickeron - Technical Analysis
Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ...
4/23/2025 - GuruFocus
Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ...
4/23/2025 - GuruFocus
Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting
4/23/2025 - Business Wire
Rock Springs Capital Management LP Decreases Stock Position in Zai Lab Limited (NASDAQ:ZLAB)
4/23/2025 - MarketBeat
B Group Inc. Acquires New Shares in Zai Lab Limited (NASDAQ:ZLAB)
4/23/2025 - MarketBeat
Capital International Investors Purchases 120,000 Shares of Zai Lab Limited (NASDAQ:ZLAB)
4/23/2025 - MarketBeat
Zai Lab Limited (NASDAQ:ZLAB) Position Boosted by Renaissance Technologies LLC
4/22/2025 - MarketBeat
Zai Lab Prepares for 2025 Annual General Meeting with Proxy Filing
4/22/2025 - TipRanks Financial Blog
Zai Lab (ZLAB) Seeks Label Expansion for Cancer Treatment in China
4/21/2025 - GuruFocus
Zai Lab gets China's acceptance for label expansion of repotrectinib
4/21/2025 - Seeking Alpha - Healthcare
Zai Lab Ltd (ZLAB) Announces Acceptance of sNDA for Repotrectinib in China ZLAB stock news
4/21/2025 - GuruFocus
Zai Lab Announces Acceptance of Supplemental New Drug Application for Repotrectinib for ...
4/21/2025 - GuruFocus
China Accepts Zai Lab's (ZLAB) Drug Application for Cancer Treatment ZLAB Stock News
4/21/2025 - GuruFocus
Zai Lab Announces Acceptance of Supplemental New Drug Application for Repotrectinib for ...
4/21/2025 - GuruFocus
Income Statement
Total Revenue (TTM)
$398.99M
EBITDA (TTM)
-$270.26M
EBIT (TTM)
-$282.12M
Net Income (TTM)
-$257.10M
Balance Sheet
Total Assets (Q)
$1.19B
Total Debt (Q)
$153.47M
Total Liabilities (Q)
$344.86M
Book Value Per Share (Q)
$78.03
Cash Flow
Cash from Operations (TTM)
-$214.87M
Cash from Investing (TTM)
-$375.19M
Cash from Financing (TTM)
$349.89M
Net Change in Cash (TTM)
-$240.48M
Filings
Filing Date
Thursday, February 27, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Loading...
Beta
0.91
7-Day Total Return
7.17%
30-Day Total Return
-16.03%
60-Day Total Return
16.29%
90-Day Total Return
18.06%
Year to Date Total Return
28.34%
1-Year Total Return
101.52%
2-Year Total Return
-8.48%
3-Year Total Return
-19.49%
5-Year Total Return
-49.23%
52-week Low
Apr 30, 2024 - $15.67
52-week High
Mar 28, 2025 - $39.77
Valuation
Market Cap
$3.50B - Mid Cap
Enterprise Value
$2.87B
Price/Sales (TTM)
0.82
Price/Book (Q)
0.41
Dividends and Shares
Shares Outstanding
10.27M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.zailaboratory.com
Phone Number
86 21 6163 2588
Address
Jinchuang Plaza
Building 1, 4th Floor - 4560 Jinke Road
Pudong Shanghai, 201210
Country
China
Year Founded
2013
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience... more
NASDAQ 04/29/2025 4:00PM Eastern Quotes delayed